Performance Updates

Want to track the performance of this manager?

Click the button below to sign up to receive monthly performance updates by email.

Track Manager
Invest Today

Want more information on investing with this manager?

If you are interested in investing in one of Marcus Eder's funds. Click the link below to get started.

Invest Today

Marcus Eder

IT-consultant

  • Aug 05, 2001
Funds
(CIAF) Crossy's Industry Analysis Fund
MODEL INCEPTION (08/05/2001) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
16+ YRS 14.83% 7.38% View Fund Stats Track Fund
RETURN PERIOD (As Of: 03/31/2018) AVG. ANNUAL RETURN S&P TOTAL RETURN ACHIEVEMENTS
10 YRS 11.91% 7.24% Beat the 75th percentile of mutual funds over 10 years.  
5 YRS 14.65% 16.37% Beat the 75th percentile of mutual funds over 5 years.  
3 YRS -0.73% 11.16% Fund has a 3 year track record.  
1 YR 19.83% 15.43% Beat the 50th percentile of mutual funds over 1 year.  
Show Fund Strategy
Click Here to View More Information About This Fund.
(CDSF) Crossys diversified Service Fund
MODEL INCEPTION (06/06/2004) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
13+ YRS 12.82% 8.54% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CEOF) Crossy's Energy Opportunity Fund
MODEL INCEPTION (09/04/2001) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
16+ YRS 7.34% 7.97% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CFSF) Crossy Financial Services Fund
MODEL INCEPTION (06/14/2003) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
14+ YRS 10.24% 9.23% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CLVF) Crossy's Lifesciences Value Fund
MODEL INCEPTION (01/24/2003) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
15+ YRS 16.38% 9.98% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CSWF) Crossy Software Fund
MODEL INCEPTION (05/12/2003) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
14+ YRS 16.14% 9.27% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CTCF) Crossy's Telecom Fund
MODEL INCEPTION (01/16/2004) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
14+ YRS 9.94% 8.42% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CTXF) Crossy Technology Fund
MODEL INCEPTION (04/01/2003) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
15+ YRS 14.25% 9.57% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
(CWBF) Crossy's Wellbeing Fund
MODEL INCEPTION (08/20/2003) AVG. ANNUAL RETURN S&P TOTAL RETURN Actions
14+ YRS 14.69% 9.08% View Fund Stats Track Fund
Show Fund Strategy
Click Here to View More Information About This Fund.
Achievements
  • CLVF Beat the top performing mutual fund over 10 years.
    Mar 31, 2018
  • CIAF Beat the 75th percentile of mutual funds over 5 years.
    Mar 31, 2018
  • CDSF Beat the 75th percentile of mutual funds over 3 years.
    Mar 31, 2018
  • CDSF Beat the 75th percentile of mutual funds over 1 year.
    Mar 31, 2018

Crossy's Lifesciences Value Fund

CLVF | Fund Positions by Styles
Color Name Allocation Today
Unclassified Market Cap : Unclassified Style 35.21% -0.11%
Micro Cap : Value 20.98% -2.63%
Small Cap : Growth 14.71% -4.51%
Small Cap : Blend 8.29% -1.10%
Micro Cap : Growth 7.36% -5.02%
Mid Cap : Growth 3.98% -3.90%
Micro Cap : Blend 3.42% -2.79%
Large Cap : Growth 2.74% -2.41%
Large Cap : Value 1.83% -2.59%
Small Cap : Value 1.49% -2.95%
Large Cap : Blend 0.00% -3.14%
CLVF | Price History
CLVF | Fund Information

The information below pertains to model data only.

Fund Manager: Total Model Net Assets:
Marcus Eder $10,106,952.24
Inception: Ticker Symbol: # of Securities:
January 24, 2003 CLVF 82
Description:

The fund tries to maintain a broad but yet balanced participation in lifescience related markets and segments: Big Pharma, Specialty Pharma, Generics, Contract Manufacturers, Medical Device Makers, Medical Supplies, Biotechs Each segment is evaluated on criteriae fund management deems appropriate : for example for Biotechs, primarily pipeline analysis in conjunction with financial health (curRatio, QuickRatio) and valuation criteriae (target market potential, Price/Book, pipeline stage etc) For generics, marketcap, price/sales and growth rates are used for the selection process.. The fund centers itself on a "value" theme - the prime objective is to find grossly undervalued situations. However this objective is always balanced versus growth motivation inherent in life science based industries. Companies with a "balanced" portfolio, are particularly welcomed to the portfolio, since the fund manager attributes such situations with markedly reduced risk. Balanced portfolio describes a company status, where the cash requirements of an upcoming growth or R&D intensive business can be met by cash flow generated by another operation within the company. Such a business won't have to worry about cash burn rates and hit the capital markets for refinancing purposes as often as non-balanced biotechs would need to do. Prime example : Repligen (RGEN) with it's bulk biomaterials Protein-A franchise. Companies are de-emphasized, partially unloaded or sold entirely if valuation criteriae are reached which make further appreciation highly unlikely versus the industry average. The fund started with a more cautious approach instantly, as the climate of 2002 didn't favour risk taking gambits. Consequently initial biotech positions were small-size only. Higher weighting was used in biotechs with exceptional low valuation (such as BCRX) or if at least cash-flow positive status has been achieved (such as BTGC). Also initially, oversea's pharma and generics companies were overweight as were makers of diagnostic products (such as IMA, TRIB and BIOI) Against the general depressed and risk-intolerant market attitude as of summer 2008, the fund has changed to a risk avoiding strategy by emphasizing cash-flow and revenue trends over promising product-pipelines and future market potential. Consequently, the generics, medical equipment and biopharm API exposure was hiked while the biotech exposure was reduced. This is magnified by the outlook of blockbuster drugs coming off-patent over the next 5-10 years. Attractively valued imho are firms like MYL, KG, PRX, DRUG.OB, HITK, CPD, CBM .. among others On an additional note, the fund is aware of the increased role generic pharma is about to play in the future and tries to position itself to capitalize on the underlying developments.

CLVF | Turnover
Last Month N/A
Last 3 Months 3.23%
Last 6 Months 13.36%
Last 12 Months 32.5%
CLVF | 5 Most and Least Profitable
5 MOST PROFITABLE 5 LEAST PROFITABLE
Position Symbol Gains
1 CBM $1,219,754.97
2 LCI $1,134,867.56
3 CDXS $967,159.83
4 SPPI $577,285.95
5 MZRTF $571,214.87
Position Symbol Gains
1 MSLI -$443,962.87
2 RDHL -$321,313.66
3 MNK -$296,331.00
4 PLXP -$288,355.20
5 TEVA -$235,386.56
CLVF | Skill Metrics
All Positions
Winning % 46.53%
Avg. Gain/Loss Ratio 2.72
CLVF | Fund Positions by Sectors and Industries
Color Name Allocation Today
Health Care 82.42% -1.92%
Materials 11.25% -2.77%
Consumer Discretionary 3.74% -4.82%
Unallocated 2.41% -0.90%
Technology 0.19% -1.79%
CLVF | Recent Returns vs Major Indexes
Beating Today MTD QTD YTD
CLVF -0.02% 2.26% 2.26% -3.40%
S&P 500 -0.85% 1.11% 1.11% 0.00%
NASDAQ -1.27% 0.00% 0.00% 0.00%
CLVF | Recent Returns
Period Returns S&P 500 Returns Returns VS S&P 500
Last 7 Days 1.48% 0.00% 1.48%
Last 30 Days -1.76% 0.58% -2.34%
Last 3 Months -8.07% -5.03% -3.04%
Last 6 Months -4.85% 4.54% -9.39%
Last 12 Months 2.12% 15.32% -13.20%
Last 2 Years 6.52% 32.28% -25.76%
Last 3 Years -25.95% 34.15% -60.10%
Last 5 Years 112.84% 88.63% 24.21%
Last 10 Years 447.16% 138.78% 308.38%
Since Inception 910.93% 321.38% 589.55%
(Annualized) 16.38% 9.89% 6.49%
Data as of: 04/21/2018
CLVF | Alpha/Beta VS. S&P 500
Alpha 0%
Beta 0
R-Squared 0
CLVF | 5 Best and Worst Returns
5 BEST 5 WORST
Position Symbol Inception Return
1 CDXS 281.31%
2 MZRTF 201.75%
3 ZGNX 165.87%
4 AXGN 141.15%
5 CBM 128.20%
Position Symbol Inception Return
1 VNSN -99.99%
2 RSLS -99.90%
3 ENUMQ -99.82%
4 CLSN -93.68%
5 RXII -92.23%